Overview Resmetirom is a novel medication developed for treating a serious liver condition called nonalcoholic steatohepatitis (NASH), particularly when accompanied by liver fibrosis. As NASH becomes increasingly common due to rising obesity and metabolic syndromes, Resmetirom presents a promising, targeted approach to therapy. Approved under the brand name Rezdiffra, this oral medication is a selective thyroid hormone receptor-β (THR-β) agonist designed to reduce liver fat, inflammation, and fibrosis. What is Resmetirom? Resmetirom is a selective thyroid hormone receptor beta (THR-β) agonist, primarily used for treating NASH. Unlike general thyroid hormone therapies, it targets the liver specifically, reducing systemic side effects.…